Nascent Biotech Inc. | Income Statement
Fiscal year is April-March. All values USD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
3,000.00
-
Cost of Goods Sold (COGS) incl. D&A
1.10
-
-
-
-
Gross Income
1.10
-
-
-
-
SG&A Expense
520.70
2,144.80
5,444.40
2,052.20
2,221.80
EBIT
521.80
2,144.80
5,444.40
947.80
2,221.80
Unusual Expense
1,334.50
5.10
1,576.10
3.50
0.30
Non Operating Income/Expense
-
21.70
-
479.70
-
Interest Expense
11.90
24.00
280.50
54.10
-
Pretax Income
1,868.30
2,152.10
4,148.70
1,376.90
2,221.30
Income Tax
-
-
-
240.00
-
Consolidated Net Income
1,868.30
2,152.10
4,148.70
1,136.90
2,221.30
Net Income
1,868.30
2,152.10
4,148.70
1,136.90
2,221.30
Net Income After Extraordinaries
1,868.30
2,152.10
4,148.70
1,136.90
2,221.30
Net Income Available to Common
1,868.30
2,152.10
4,148.70
1,136.90
2,221.30
EPS (Basic)
0.59
0.15
0.21
0.05
0.09
Basic Shares Outstanding
3,147.70
13,987.00
19,773.30
21,799.00
25,883.80
EPS (Diluted)
0.59
0.15
0.21
0.05
0.09
Diluted Shares Outstanding
3,147.70
13,987.00
19,773.30
23,678.30
25,883.80
EBITDA
520.70
2,144.80
5,444.40
-
2,221.80
Non-Operating Interest Income
-
0.10
0.00
0.10
0.10
About Nascent Biotech
View Profile
